| Ilaris (canakinumab) / Novartis |
| Not yet recruiting | 2 | 52 | Europe | Ilaris, Solution for injection/infusion, Ilaris | Imperial College London, Novartis Pharmaceuticals UK Limited | Alcoholic Hepatitis, Inflammation of the liver caused by excessive alcohol consumption, Diseases [C] - Digestive System Diseases [C06] | | | | |
NCT02272946: Effect of IL--1β Inhibition on Inflammation and Cardiovascular Risk |
|
|
| Completed | 2 | 43 | US | Canakinumab, IL--1β, Placebo | Priscilla Hsue, MD, Massachusetts General Hospital | HIV, Cardiovascular Disease | 02/21 | 12/21 | | |
2020-003966-38: Study of the efficacy and safety of various anti-inflammatory agents in participants with mild cognitive impairment or mild Alzheimer's Disease |
|
|
| Not yet recruiting | 2 | 900 | Europe | Canakinumab, ACZ885, Solution for injection, Ilaris | Novartis Pharma AG, Novartis Pharma AG | Mild cognitive impairment due to Alzheimer’s disease and mild Alzheimer’s disease, Study to evaluate the efficacy, safety, tolerability and pharmacokinetics of various anti-inflammatory agents in patients with early Alzheimer's disease, Diseases [C] - Nervous System Diseases [C10] | | | | |
NCT04795466: Study of the Efficacy and Safety of Various Anti-inflammatory Agents in Participants With Mild Cognitive Impairment or Mild Alzheimer's Disease |
|
|
| Terminated | 2 | 34 | Europe, US, RoW | Canakinumab, ACZ885, Placebo | Novartis Pharmaceuticals | Mild Cognitive Impairment, Alzheimer Disease | 03/24 | 03/24 | | |
CHORUS, NCT04905316: A Study of Canakinumab With Chemotherapy, Radiation Therapy, and Durvalumab in People With Lung Cancer |
|
|
| Active, not recruiting | 2 | 41 | US | Canakinumab, ACZ885, Durvalumab, Radiation therapy, Chemotherapy | Memorial Sloan Kettering Cancer Center, Novartis Pharmaceuticals | Non-small Cell Lung Cancer | 05/25 | 05/25 | | |
| Recruiting | 2 | 1300 | Europe | Canakinumab 150mg/ml solution for injection, Placebo | Imperial College London, Novartis Pharmaceuticals | Alcoholic Hepatitis | 05/24 | 05/24 | | |
NCT05467800: Study of Canakinumab in Patients With Myelofibrosis |
|
|
| Recruiting | 2 | 10 | US | Canakinumab | John Mascarenhas | Primary Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis, ET-MF, Post-polycythemia Vera Related Myelofibrosis, PV-MF | 01/25 | 07/26 | | |
NCT04814368 / 2020-003631-21: A Safety and Efficacy Study of Anti-inflammatory (Canakinumab) and Cartilage Stimulating (LNA043) Drugs Injected Into the Knee Joint of Participants With Knee Osteoarthritis (OA) |
|
|
| Terminated | 2 | 23 | Europe, US, RoW | canakinumab, ACZ885, LNA043, Placebo to canakinumab | Novartis Pharmaceuticals | Knee Osteoarthritis | 06/24 | 06/24 | | |
| Recruiting | 2 | 50 | US | Canakinumab, ACZ885, Ilaris, Quality-of-Life Assessment, Quality of Life Assessment | M.D. Anderson Cancer Center | Lung Carcinoma, Stage I Lung Cancer AJCC v8, Stage IA1 Lung Cancer AJCC v8, Stage IA2 Lung Cancer AJCC v8, Stage IA3 Lung Cancer AJCC v8, Stage IB Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIA Lung Cancer AJCC v8, Stage IIB Lung Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Stage IIIB Lung Cancer AJCC v8, Stage IIIC Lung Cancer AJCC v8 | 12/25 | 12/25 | | |
NCT05641831: Canakinumab for the Prevention of Progression to Cancer in Patients With Clonal Cytopenias of Unknown Significance, IMPACT Study |
|
|
| Recruiting | 2 | 94 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bone Marrow Aspiration and Biopsy, Canakinumab, ACZ885, Ilaris, Chest Radiography, Chest X-ray, Echocardiography, EC, Placebo Administration, Quality-of-Life Assessment, Quality of Life Assessment | Uma Borate | Clonal Cytopenia of Undetermined Significance | 12/25 | 12/28 | | |
NCT06038526: Evaluation of Canakinumab in High-Risk Former-Smokers |
|
|
| Recruiting | 2 | 75 | US | Biospecimen Collection, Biological Sample Collection, Biospecimen Collected, Specimen Collection, Bronchoscopy, Canakinumab, ACZ885, Ilaris, Carbon Monoxide Measurement, Carbon Monoxide, CMONOX, Survey Administration | Peter Shields | Cigarette Smoking-Related Carcinoma, Lung Carcinoma | 12/25 | 12/25 | | |
NCI-2019-08494, NCT04239157: A Phase II, Open-Label, Study of Subcutaneous Canakinumab, an Anti-IL-1β Human Monoclonal Antibody, for Patients With Low or Int-1 Risk IPSS/IPSS-R Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia |
|
|
| Recruiting | 2 | 60 | US | Canakinumab, ACZ885, Ilaris | M.D. Anderson Cancer Center, National Cancer Institute (NCI), Novartis | Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia, Recurrent Myelodysplastic Syndrome, Refractory Chronic Myelomonocytic Leukemia, Refractory Myelodysplastic Syndrome | 12/26 | 12/26 | | |
NCT05237713: Efficacy and Safety of Canakinumab for the Treatment of Anemia in LR-MDS Patients |
|
|
| Terminated | 2 | 10 | Europe | Canakinumab Injection, Ilaris(R) | University of Leipzig, Novartis Pharmaceuticals | Anemia, Myelodysplastic Syndromes | 02/24 | 02/24 | | |
NCT04798339: Canakinumab With Darbepoetin Alfa in PTs With Lower-Risk MDS Who Have Failed ESA |
|
|
| Recruiting | 1/2 | 41 | US | Canakinumab Injection, Ilaris, Darbepoetin Alfa, Aranesp | H. Lee Moffitt Cancer Center and Research Institute, Novartis Pharmaceuticals | Myelodysplastic Syndromes | 10/24 | 10/25 | | |
NCT03936894: Single Escalating Dose Pilot Trial of Canakinumab (ILARIS®) in Duchenne Muscular Dystrophy |
|
|
| Active, not recruiting | 1/2 | 3 | US | Canakinumab Injection [Ilaris] | Children's National Research Institute, Foundation to Eradicate Duchenne | Duchenne Muscular Dystrophy | 04/24 | 04/24 | | |
NCT06006286: A Study Evaluating Atezolizumab and Bevacizumab Plus ADI-PEG 20 in Patients With Locally Advanced / Metastatic Hepatocellular Carcinoma |
|
|
| Withdrawn | 1/2 | 10 | US | Atezolizumab, Bevacizumab, ADI-PEG 20 | M.D. Anderson Cancer Center | Metastatic Hepatocellular Carcinoma | 11/23 | 11/23 | | |
